Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Dermatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Dermatology Other
    Converting to Sirolimus From Calcineurin Inhibitors Reduces Risk of Skin Cancer in Kidney Transplant Patients: Presented at Renal Week 2009 - (DGDispatch)
    Spinosad Better Than Permethrin for Pediculosis Capitis in Children: Presented at AAP - (DGDispatch)
    Topical Onychomycosis Treatment More Effective Than Oral Treatment : Presented at EADV - (DGDispatch)
    Mycophenolate Mofetil Benefits Patients With Pemphigus Vulgaris: Presented at EADV - (DGDispatch)
    Health Canada Approves Telavancin for Complicated Skin, Skin Structure Infections - (DGNews)

    News archive

     Recent webcasts/CME - Dermatology Other
      The Prevention and Treatment of Pressure Ulcers
      Contemporary Options for the Management of Scars
      Pediatric and Adolescent Sports-Related Injuries and Ailments
      The Wound Healing Process
      Current Concepts in Healing Chronic Diabetic Foot Ulcerations

      Webcasts/CME archive

       Recent cases - Dermatology Other
        Yellow Nail Syndrome
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)
        Ulcerative Leg Nodules in a Transplant Recipient
        Pearly Penile Papules

        Cases archive
          




        my personal edition > dermatology other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Dusa Pharmaceuticals Reports Brazilian Regulatory Approval for Levulan (Aminolevulinic Acid Hcl) Topical Solution

        Product Launch Expected by Early '07

        WILMINGTON, MA -- October 17, 2006 -- DUSA Pharmaceuticals, Inc. today reported that Stiefel Laboratories, Inc., DUSA's marketing partner for Latin America, has been informed by ANVISA, the Brazilian drug regulatory authorities, that the Levulan® Kerastick® (aminolevulinic acid Hcl) topical solution has been approved in Brazil. With DUSA's support, Stiefel Laboratories completed the regulatory filing with ANVISA during the second quarter of this year.

        Robert Doman, DUSA's President and COO, stated "We are very pleased with the joint efforts between the two companies and progress that has been made since the signing of our agreement with Stiefel Laboratories in January. This represents a significant step in our goal of expanding the distribution of Levulan PDT beyond the North American market."

        Additional launches are expected to follow in a number of other Latin American countries, subject to regulatory approvals.

        In January 2006, DUSA Pharmaceuticals, Inc. announced that it entered into an exclusive marketing, distribution and supply agreement for Latin America with Stiefel Laboratories, Inc. The agreement covers current and future uses of DUSA's proprietary Levulan ® Kerastick ® for photodynamic therapy (PDT) in dermatology.


        SOURCE: DUSA Pharmaceuticals, Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send